TMDX vs. MASI, ITGR, LIVN, CNMD, INMD, SLNO, BLFS, ZYXI, AXGN, and EDAP
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Masimo (MASI), Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), Zynex (ZYXI), AxoGen (AXGN), and Edap Tms (EDAP). These companies are all part of the "electromedical equipment" industry.
TransMedics Group (NASDAQ:TMDX) and Masimo (NASDAQ:MASI) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
TransMedics Group has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, Masimo has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
In the previous week, TransMedics Group had 4 more articles in the media than Masimo. MarketBeat recorded 23 mentions for TransMedics Group and 19 mentions for Masimo. Masimo's average media sentiment score of 0.56 beat TransMedics Group's score of 0.44 indicating that Masimo is being referred to more favorably in the news media.
Masimo has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Masimo has a net margin of 4.01% compared to TransMedics Group's net margin of -3.43%. Masimo's return on equity of 13.26% beat TransMedics Group's return on equity.
99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 86.0% of Masimo shares are held by institutional investors. 7.0% of TransMedics Group shares are held by insiders. Comparatively, 9.7% of Masimo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
TransMedics Group currently has a consensus target price of $133.88, suggesting a potential downside of 2.41%. Masimo has a consensus target price of $143.57, suggesting a potential upside of 14.44%. Given Masimo's higher probable upside, analysts plainly believe Masimo is more favorable than TransMedics Group.
Masimo received 364 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 63.89% of users gave Masimo an outperform vote while only 55.63% of users gave TransMedics Group an outperform vote.
Summary
Masimo beats TransMedics Group on 12 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransMedics Group Competitors List
Related Companies and Tools
